Research Papers:
miR-382 inhibits tumor growth and enhance chemosensitivity in osteosarcoma
PDF | HTML | Supplementary Files | How to cite
Metrics: PDF 2629 views | HTML 2651 views | ?
Abstract
Meng Xu1, Hua Jin2, Cheng-Xiong Xu3, Bo Sun4, Zhi Mao1, Wen-Zhi Bi1, Yan Wang1
1 Department of Orthopaedics, The General Hospital of Chinese People's Liberation Army, Beijing, China.
2 Department of Pharmaceutical Sciences, College of Pharmacy, University of South Florida, Tampa, FL, USA.
3 Departments of Molecular Oncology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA.
4 State Key Laboratory of Bioelectronics, School of Biological Science and Medical Engineering, Southeast University, Nanjing, China.
Correspondence to:
Dr. Cheng-Xiong Xu, e-mail: xuchengxiong@hanmail.net
Yan Wang, e-mail: leptin1@gmail.com
Keywords: miR-382, osteosarcoma growth, chemoresistance
Received: July 11, 2014 Accepted: August 28, 2014 Published: September 05, 2014
ABSTRACT
Dysregulation of miRNAs is involved in osteosarcoma (OS). Here, we demonstrate that miR-382 is decreased in specimens of OS patients with a poor chemoresponse compared to those with a good chemoresponse. In addition, our clinical data show that decreased miR-382 was associated with poor survival in OS patients. Overexpression of miR-382 inhibited cell growth and chemoresistance by targeting KLF12 and HIPK3, respectively. In contrast, inhibition of miR-382 or overexpression of target genes stimulated OS cell growth and chemoresistance both in vitro and in vivo. Taken together, these findings suggest that miR-382 is a tumor suppressor miRNA and induction of miR-382 is a potential strategy to inhibit OS progression.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 2418